Skip to main content
Premium Trial:

Request an Annual Quote

IntegenX Gets DoD Contract for Pathogen ID System

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sample prep firm IntegenX today said it has been awarded a $2.8 million contract by the US Department of Defense to develop a system for the rapid detection and identification of genetically engineered bacteria and viruses.

The contract from DoD's Defense Threat Reduction Agency is the first phase of a possible 22-month, $14.8 million contract, the Pleasanton, Calif.-based company said in a statement. The integrated sample-to-sequence system it is developing will also be used to detect and identify medically relevant bacteria and viruses, as well as emerging pathogens.

The company will use its Universal Sample Preparation Module to purify DNA from pathogen targets contained in complex matrices. The purified material will be presented to an IntegenX library construction module, then an amplification module, and finally a next-generation sequencing module. The USPM was developed with an earlier DOD contract.

IntegenX plans to apply its Move technology to integrate the complete workflow of the ISS system. The system will be less than three cubic feet, it said.

Formerly called Microchip Biotechnologies, IntegenX manufactures automated DNA- and RNA-based sample-preparation systems for life sciences, applied sciences, and diagnostics markets.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.